4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester

CAS NO.：917392-54-2

Purity: ≥99%
Appearance: Pale-yellow or off-white solid
Product Manager Email: crystal@coreychem.com

Product Name:	4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester
Synonyms:	4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester;4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)-benzoic acid Methyl ester;Methyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate, ;Nilotinib Hydrochloride Monohydrate Impurity G;Nilotinib Hydrochloride Monohydrate EP Impurity G
CAS:	917392-54-2
MF:	C18H16N4O2
MW:	320.35
Melting point	148 – 150°C
Boiling point	538.6±60.0 °C(Predicted)
density	1.258
storage temp.	2-8°C
solubility	Chloroform (Slightly), DMSO (Slightly)
pka	2.70±0.12(Predicted)
Appearance	Pale Yellow to Light Beige Solid
HS code	2934999099
Transport Information	Non-hazardous goods

Frequently Asked Questions：

1. What is the main purpose of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester?
Used as a pharmaceutical impurity reference standard for the pharmaceutical quality research of Nilotinib (Tasigna), a targeted therapeutic agent for chronic myeloid leukemia, and also acts as a key synthetic intermediate for nilotinib.
2.What are the product sources and formation pathways?
*In the synthetic route of nilotinib, this methyl ester is an upstream intermediate. It undergoes alkaline hydrolysis to yield the corresponding carboxylic acid, followed by amide condensation to finally obtain nilotinib active pharmaceutical ingredient (API).
*Incomplete hydrolysis will leave residual methyl ester in the finished nilotinib product, forming a process‑related impurity, namely Pharmacopoeia EP Impurity G. It is a known related substance that must be strictly controlled for nilotinib API..
3. What physical & physicochemical properties require special attention during usage?
It is prone to hydrolysis. Do not keep the sample solution for an extended period in an alkaline mobile phase; the sample solution should preferably be freshly prepared prior to testing. Overnight storage after preparation will lead to higher test results (carboxylic‑acid degradation peak appears). In addition, it exhibits thermal‑sensitivity and photosensitivity; prolonged storage of the solid at elevated temperature will gradually cause darkening of colour.
4.What are the solubility and hygroscopicity of this product?
It is soluble in DMSO, DMF and dichloromethane, and practically insoluble in water. Upon exposure to water under alkaline conditions, the methyl ester readily hydrolyzes to form the corresponding carboxylic‑acid impurity.
5. What precautions should be taken in practical operations?
Store sealed under refrigeration at 2‑8 °C. Allow the container to warm up to room temperature before opening after removal from the refrigerator.
Store in an amber bottle and protect from light.
Prepare sample solutions freshly; avoid prolonged storage under alkaline conditions to prevent hydrolysis and formation of carboxylic‑acid degradant.
Prioritize organic solvents for dissolution; direct dissolution of the solid in water is prohibited.
The drying temperature shall not exceed 50 °C to avoid high‑temperature exposure.
Take dust‑proof protective measures during weighing.
6. Appearance：

7. COA
Cas 917392-54-2 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester COA

Application 1: What is the main use of this product in the pharmaceutical field?
Answer: Pharmaceutical Impurity Reference Standard (Primary Market Application) : Used for quality‑related studies of Nilotinib (Tasigna, a targeted drug for chronic myeloid leukemia); applied in HPLC testing, analytical method validation, generic drug submission, and routine QC assay calibration. It is mainly purchased by pharmaceutical enterprises, CROs and pharmaceutical testing laboratories.
Noted: It is only intended for analytical testing and scientific research and shall not be administered directly to humans.
Application 2: Other Pharmaceutical Synthetic usage？
Answer:It’s also Used for the synthesis of nilotinib active pharmaceutical ingredient (API). It can also serve as a heterocyclic pharmaceutical building block for laboratory‑scale research and development of new Bcr‑Abl kinase inhibitor drugs.
Application 3: What are the uses of this research direction? M
Answer: Material for Drug Filing Studies: Employed for impurity limit investigation and stability test studies.

Packing size:
Sample: brown glass bottle
5kg/aluminium foil bag
25kg/Fiber can
Packing photo:

Storage temp：
Keep in dark place, Store sealed under refrigeration at 2‑8 °C
Expiration date：
About 12 months if properly stored